Gyre Therapeutics, Inc.
Sağlık
COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.
$4.3
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
WebsiteAnalysis (Turkish): GYRE Hissesi Caiz mi, Helal mi? Gyre Therapeutics, Inc. Katılım Analizi